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Obesity reduces the pro-angiogenic potential of adipose tissue
stem cell-derived extracellular vesicles (EVs) by impairing
miR-126 content: impact on clinical applications
G Togliatto1,3, P Dentelli1,3, M Gili1, S Gallo1, C Deregibus1, E Biglieri1, A Iavello1, E Santini2, C Rossi2, A Solini2, G Camussi1 and MF Brizzi1
BACKGROUND/OBJECTIVES: Soluble factors and cell-derived extracellular vesicles (EVs) are crucial tissue repair mediators in cell-
based therapy. In the present study, we investigate the therapeutic impact of EVs released by adipose tissue-derived stem cells
(ASCs) recovered from obese subjects’ visceral and subcutaneous tissues.
METHODS: ASCs were recovered from 10 obese (oASCs) and 6 non-obese (nASCs) participants and characterized. In selected
experiments, nASCs and oASCs were cultured with palmitic acid (PA) or high glucose (HG), respectively. EVs from obese (oEVs) and
non-obese (nEVs) subjects’ visceral and subcutaneous ASCs were collected after ultracentrifugation and analyzed for their cargo:
microRNA-126 (miR-126), vascular endothelial growth factor (VEGF), and matrix metalloproteinase 2 (MMP-2), and for their
biological effects on endothelial cells (ECs). Western blotting analysis and loss- and gain-of function experiments were performed.
RESULTS: oEVs show impaired angiogenic potential compared with nEVs. This effect depends on EV cargo: reduced content of
VEGF, MMP-2 and, more importantly, miR-126. We demonstrate, using gain- and loss-of-function experiments, that this reduced
miR-126 content leads to Spred1 upregulation and the inhibition of the extracellular signal–regulated kinase 1/2 mitogen-activated
protein kinase pathway in ECs. We also show that PA treatment of nASCs translates into the release of EVs that recapitulate oEV
cargo. Moreover, HG treatment of oASCs further reduces miR-126 EV content and EV-mediated in vitro angiogenesis. Finally,
impaired pro-angiogenic potential is also detected in EVs released from obese subcutaneous adipose tissue-derived ASCs.
CONCLUSIONS: These results indicate that obesity impacts on EV pro-angiogenic potential and may raise concerns about the use
of adipose tissue-derived EVs in cell-based therapy in the obese setting.
International Journal of Obesity (2016) 40, 102–111; doi:10.1038/ijo.2015.123
INTRODUCTION
Obesity is a pandemic health problem.1 In particular, visceral fat
accumulation results in adipocyte and adipose tissue function
abnormalities leading to a plethora of diabetogenic and
atherogenic abnormalities, which often directly contribute to
cardiovascular disease.2 Adipose tissue is connective tissue
specializes in accumulating fat into adipocytes. Besides adipo-
cytes, adipose tissue also contains mesenchymal stem cells
(MSCs), denoted as adipose-derived stem cells (ASCs).3–5 Similarly
to stem cells present in other different adult tissues, ASCs are
multi-potent cells that are able to differentiate into mesenchymal
tissues.6 The fact that ASCs act as an important source of cells for
tissue regeneration and cell-based therapy means that they have
attracted particular interest.7 Although ASCs have been shown to
participate in tissue repair, their precise mechanism of action is
still open to question. It is generally accepted that their most
relevant mechanism proceeds via paracrine actions.8–10 A large
amount of data has more recently indicated that ASCs use
membrane-derived small vesicles, denoted as cell-derived extra-
cellular vesicles (EVs), as well as the secretion of soluble factors, to
repair damaged tissues.11,12 EVs, including exosomes and micro-
vesicles, are shed from many cell types and have been shown to
have important roles in cell–cell communication.13,14 It has also
been shown that EVs can release various active molecules,
including signaling molecules, mRNAs and microRNAs (miRs), in
both physiological and pathological settings.15 Recent in vitro and
in vivo studies have demonstrated that EVs have a relevant role in
inflammatory diseases, including atherosclerosis, by transferring
pro-angiogenic factors, such as growth factors (vascular endothe-
lial growth factor (VEGF), platelet-derived growth factor (PDGF)),
and matrix metalloproteinases (MMP-2, MMP-9) into target cells.16
Data on the pro-angiogenic potential of endothelial progenitor
cell-derived EVs in a mouse model of hind limb ischemia have
been provided.17 Moreover, it has also been shown that MSC-
derived MVs can protect against ischaemia–reperfusion-induced
acute and chronic kidney injury.18–20 Finally, the healing proper-
ties of miRs that are carried by MSC-derived EVs have also been
provided.21
The activation of cells by chemical and physical stimuli,
including hypoxia and shear stress, is associated with EV
release.22 In fact, circulating EVs are more abundant in a number
of clinical settings, including diabetes and cardiovascular
disease.23,24 An important feature of EVs is their heterogenic
cargo. Indeed, EV cargo can vary according to challenges by
different stimuli, while differing cell types challenged with the
same stimulus can release EVs with different cargo.22 Although
general EV functions have been the topic of recent studies in
various pathological settings, no data are currently available on EV
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functional activity in an obese setting. Furthermore, it is still
unknown whether ASCs derived from visceral/subcutaneous
adipose tissue in obese patients can release EVs, which carry
different components than those released by non-obese subjects.
This would be of particular interest given their potential clinical
impact. The present study analyzes the EV release and cargo in
adipose tissue-derived ASCs of obese non-diabetic patients,
paying particular attention to their pro-angiogenic activity.
MATERIALS AND METHODS
Reagents and antibodies are reported in Supplementary Table S1 of
Supplementary Information.
Patients and controls
A total of 10 obese and 6 non-obese subjects (controls) who underwent
abdominal surgery in our clinic were included in the study. Clinical
characteristics are reported in Supplementary Table S2. Ethics approval
was obtained from the Institutional Review Board of S. Giovanni Battista
Hospital, Turin, Italy. Informed consent was obtained from all patients
according to the Helsinki Declaration. We also declare that we had no
direct contact with the participants in the present study (patients’
anonymity was guaranteed).
Isolation of human visceral and subcutaneous-derived ASCs
Paired human visceral and subcutaneous adipose tissue samples were
recovered from the above reported subjects (obese (oASC); non-obese
(nASC)) and processed as previously described.6 Freshly isolated ASCs were
characterized for their surface expression profile by fluorescence-activated
cell sorting (FACS) (CD29, CD105, CD44, CD90, CD73) and for Oct4 content
by western blotting analysis. In selected experiments, nASCs were cultured
for 2 days with 300 μmol l− 1 of palmitic acid (PA).25 Last day, nASCs were
maintained with PA, without fetal bovine serum, and processed for EV
isolation. Separately, EVs were obtained from oASCs and maintained in
culture with high glucose (HG) concentration (25mmol l− 1). In selected
experiments nASCs and oASCs were cultured in Dulbecco’s modified
Eagle’s medium (DMEM)+10% fetal bovine serum+0.5mmol l− 1 3-isobutyl-
1-methylxanthine+0.25 μmol l− 1 dexamethasone+1 μgml− 1 insulin (all
Sigma-Aldrich, St Louis, MO, USA) to stimulate adipocyte differentiation.
Cell cultures
Endothelial cells (ECs) isolated as previously described26 were cultured in
M199 without bovine calf serum for 24 h in the presence of EVs recovered
from ASCs, which were treated as indicated. Human ASCs (positive
controls; Lonza, Basel, Switzerland) were cultured in the specific Lonza
medium. The NIH 3T3L1 cell line (from ATCC, Middlesex, UK) was cultured
in adipogenic differentiating medium.
Isolation of ASC-derived EVs
oASCs and nASCs from both visceral and subcutaneous tissues were
cultured in DMEM, without fetal bovine serum, for 24 h in order to collect
EVs from supernatants. After being centrifuged at 3000 g for 30 min to
remove debris, cell-free supernatants were submitted to differential
ultracentrifugation at 10 000 and 100 000 g (Beckman Coulter Optima
L-90K ultracentrifuge; Beckman Coulter, Fullerton, CA, USA) for 3 h at 4 °C.
EVs were used freshly or stored at − 80 °C after re-suspension in DMEM,
which was supplied with 5% dimethyl sulfoxide.27,28 Frozen EVs were
washed and pelleted by 100 000 g ultracentrifugation to remove dimethyl
sulfoxide before cellular experiments. No difference in biological activity
was observed between fresh and stored EVs. The protein content of EVs
was quantified using the Bradford method (Bio-Rad, Hercules, CA, USA).
Any possible contamination was tested using a Limulus amebocyte assay
(concentration o0.1 ngml− 1). EV size distribution analysis was performed
using a NanoSight LM10 (NanoSight Ltd, Minton Park, UK). The particles in
the samples were illuminated using a laser light source, and the scattered
light was captured by camera and analyzed using Nanoparticle Tracking
Analysis. Nanoparticle Tracking Analysis automatically tracked and sized
particles according to Brownian motion and the diffusion coefficient.
Results were displayed as a frequency size distribution graph and were
outputted to a spreadsheet. In selected experiments, EVs were treated with
5 U RNAse for 3 h at 37 °C; the reaction was stopped by 10 Uml− 1 RNAse
inhibitor (Ambion, Carlsbad, CA, USA) and EVs were washed using
ultracentrifugation.18
Characterization of ASC-derived EVs
FACS analysis of ASC-derived EVs was performed as indicated19 using the
following fluorescein isothiocyanate- or phycoerythrin-conjugated anti-
bodies: CD29, CD105, CD44, CD90, CD73, CD81. Fluorescein isothiocyanate
or phycoerythrin mouse non-immune isotypic immunoglobulin G (BD
Biosciences, Franklin Lakes, NJ, USA) was used as control. Briefly, FACS
analysis of ASC-derived EVs was performed using a Guava easyCyte Flow
Cytometer (Millipore, Darmstadt, Germany). Fluorescein isothiocyanate- or
phycoerythrin-conjugated antibodies were added to a suspension of EVs
(250 particles μl− 1 in 100 μl) for 15 min at 4 °C to perform FACS analysis of
EVs. The volume was increased with a FACS flow up to 500 μl, and the
expression of surface markers was evaluated. CD63 content in EVs was
analyzed by western blotting.
EV internalization by ECs
The internalization of EVs into ECs was evaluated using confocal
microscopy (LSM5-PASCAL; Zeiss, Oberkochen, Germany). A pool of
approximately 5 × 109 EV particles was labeled with red fluorescent
PKH26 dye (2 μl ml− 1) for 30min at 37 °C, and then EVs were washed and
ultracentrifuged at 100 000 g for 1 h at 4 °C. EV pellets were suspended in
DMEM and added to ECs (1x106) for several hours in order to detect their
internalization (photomicrographs reported in the results show EV
internalization after 1 h). EVs were preincubated with blocking monoclonal
antibody (1 μgml− 1 CD29 (BD Pharmingen, Franklin Lakes, NJ, USA) in the
selected experiments.29
Western blotting analysis
Cells and EVs were lysed and protein concentrations were obtained as
previously described.30 In all, 50 μg proteins for cells and 10 μg for EVs
were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophor-
esis. Details are reported in Supplementary Information.
RNA isolation and quantitative real-time PCR
Total RNA was isolated from nASCs and oASCs using the TRIzol reagent
(Invitrogen, Carlsbad, CA, USA) and from different EVs using the mirVana
RNA Isolation Kit (Ambion), according to the manufacturer’s instructions.
RNA was quantified spectrophotometrically (Nanodrop ND-1000, Nano-
drop Technologies, Wilmington, DE, USA), because intact 18S and 28S
rRNAs were difficult to detect in the EVs. RNA from cells and EVs was then
reverse-transcribed using a TaqMan microRNA RT Kit, specific for miR-126
and miR-130a, and subjected to quantitative real-time PCR as detailed in
Supplementary Information. Gain- and loss-of-function experiments were
performed as detailed in Supplementary Information. EV isolation was then
obtained from nASCs that had been depleted of miR-126.
Tube-like structure formation (in vitro angiogenesis assay)
Tube-like structure formation from ECs treated with or without VEGF
(10 ngml− 1) and various EVs recovered from nASCs or oASCs was analyzed
as described30 and detailed in Supplementary Information.
Migration assay and cell proliferation and adhesion assay are detailed in
Supplementary Information.
Senescence assay
Senescence was evaluated by measuring acidic β-gal activity on
nASCs, nASCs+PA and oASCs.31 Details are reported in Supplementary
Information.
Statistical analysis
All data are presented as mean or percentage ± s.e.m. The D'Agostino–
Pearson test was used to test normality. Data on biometric measurements
of patients and controls, on the in vitro angiogenic, migration, adhesion
and senescence assays, on miR expression, cell proliferation, loss- and gain-
of-function experiments and finally on densitometric analysis for western
blots were analyzed using Student's t-tests for two-group comparison and
using one-way analysis of variance, followed by Tukey's multiple
comparison test, for ⩾ 3 groups. Three experiments performed in triplicate
were the minimum sample size ensuring 90% statistical power between
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experimental groups, with a probability level of 0.05, two-tailed
hypothesis. The cutoff for statistical significance was set at Po0.05
(*Po0.05, **Po0.01, ***Po0.001). All statistical analyses were carried out
using GraphPad Prism version 5.04 (GraphPad Software, Inc., La Jolla,
CA, USA).
RESULTS
ASC isolation from obese subjects and controls
Although both subcutaneous and visceral adipose tissues are
potential sources of adult stem cells,32 subcutaneous adipose
tissue has mostly been used in investigations into their potential
clinical applications.32,33 Visceral adipose tissue abundance in
pathological settings, which is connoted by drastic changes
in visceral adipose mass,32,33 has led us to evaluate its relevance in
providing ASCs or derivates for clinical purposes. ASCs were thus
isolated from visceral adipose tissues that had been recovered
from 10 obese patients (BMI430 Kgm− 2) and from 6 non-obese
subjects, used as controls (BMIo30 Kgm− 2), who all underwent
abdominal surgery.6 Clinical characteristics of the participants are
summarized in Supplementary Table S2. ASC availability was
evaluated in obese (oASCs) subjects and controls (nASCs).
There were no differences in the number of ASCs between the
two groups (mean number of cells × 103 per g fat tissue:
60.03 ± 8.10 s.e.m. oASCs, 10 samples; 58.9 ± 7.4 s.e.m. nASCs,
6 samples). Oct4 expression and CD markers were used for stem
cell characterization in both obese patients and controls
(Figures 1a and c). As reported in Supplementary Figures S1A
and C, oASCs show a reduced proliferation rate and an increased
number of senescent cells while preserving their adipo-
cyte differentiating capability (peroxisome proliferator-activated
receptor-γ2 expression).
Characterization of ASC-derived EVs
It has widely been reported that ASCs can release EVs.28 We herein
investigate whether differences in EV release can be detected
when visceral ASCs are derived from non-obese (nEVs) and obese
(oEVs) subjects. Figures 1f and g shows that no differences in
terms of EV number and size were detected by Nanosight. EV
Figure 1. Characterization of ASCs and ASC-derived EVs recovered from obese subjects and non-obese controls. (a, b) Cell extracts of visceral
adipose tissue samples recovered from obese subjects (oASCs, n= 10) and non-obese subjects (nASCs, n= 6) were analyzed by western
blotting for Oct4 content by densitometry. Protein levels were normalized to tubulin content. pos: positive control, human ASCs purchased
from Lonza; neg: negative control, adipocytes derived from NIH 3T3L1 cell line. (c, d) Table resuming flow cytometry analysis of nASC, oASC
and EV surface markers (CD29, CD44, CD105, CD90 and CD73 for ASCs and EVs and CD81 for EVs, expressed as mean± s.e.m.). (e) EV marker
CD63 showed by western blotting analysis in nEVs and oEVs derived from nASCs (n= 6) and oASCs (n= 10). (f) Number of EV particles
(mean± s.e.m.) per cell at isolation. Data refer to EVs from visceral adipose tissue samples recovered from obese subjects (oEVs, n= 10) and
non-obese subjects (nEVs, n= 6). (g) Representative images of a NanoSight analysis performed on the 100k fraction of ASC-derived EVs. Curve
1, relationship between particle distribution (left y axis) and particle size (x axis); curve 2, correlation between cumulative percentage
distribution of particles (percentile in right y axis) and particle size (x axis).
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mesenchymal origin was demonstrated by analyzing their surface
markers (Figures 1d and e). The pro-angiogenic potential
of EVs has been provided.17,28 In order to investigate whether
oEVs can be exploited for angiogenic purposes, potential EV
pro-angiogenic capability was evaluated by assaying VEGF
and MMP-2 content. Results are reported in Figure 2a
and clearly demonstrate that the content of both VEGF and
MMP-2 was lower in oEVs than in nEVs. Unexpectedly, we found
that in oASCs VEGF and MMP-2 content was increased
(Supplementary Figure S1D). Moreover, as EVs are capable of
releasing various active molecules including miRs, we decided to
evaluate the EV content of pro-angiogenic miRs, miR-126 and
miR-130a. Data reported in Figure 2b demonstrate that miR-126
content, but not miR-130a, was reduced in oEVs despite no
significant differences detected in the cells (Supplementary
Figure S1E).
Thus data indicate that oEVs may be less effective in inducing
pro-angiogenic signals.
nEV and oEV internalization and EC biological effects
EVs have recently been the focus of increased levels of attention in
their role as well-preserved evolutionary cell-to-cell communica-
tion mechanisms.13,14 In this regard, internalized EVs are known to
modulate vessel formation by inducing angiogenesis or promot-
ing EC survival.17,34 Thus, nEVs and oEVs that are labeled with
PKH26 dye were evaluated for incorporation into target cells. nEVs
and oEVs were incorporated by ECs as shown in Figure 2c.
Moreover, we show that this internalization depends on the
presence of the CD29 surface marker (Figure 2c). Functional
studies were performed to evaluate the biological relevance of EV
internalization into ECs. To this end, we analyzed the ability of
nEVs and oEVs to induce EC migration and tube-like structure
formation. The results reported in Figures 2d and e demonstrate
that oEVs are impaired in their ability to induce migration and
angiogenesis in vitro as compared with nEVs. No significant
reduction in the number of viable cells was detected.
Figure 2. nEV and oEV pro-angiogenic capability. (a) EVs recovered from the visceral ASCs of obese subjects (oEVs) and of non-obese subjects
(nEVs) were analyzed by western blotting for VEGF and MMP-2 content and normalized to CD63 and β-actin content. IL-3-treated ECs were
used as a positive control (c+). The results are representative of all nEVs and oEVs samples (n= 6 and n= 10, respectively) (**Po0.01 for
MMP-2 and VEGF content in oEVs vs nEVs). (b) miR‐126 and miR-130 expression was evaluated by quantitative real-time PCR on nEVs and oEVs
recovered from nASCs and oASCs, respectively. Data normalized to RNU6B are representative of all samples (nEVs, n= 6; oEVs, n= 10)
(***Po0.001 oEVS vs nEVs). (c) Representative images obtained by confocal microscope of ECs treated for 1 h without (none) or with PHK26-
labeled nEVs or oEVs to evaluate EV internalization. EV internalization was also evaluated either in the presence or in the absence of the
blocking antibody against CD29. The results are representative of four different experiments performed in triplicate (n= 4). Scale bars indicate
10 μm. (d) Representative photomicrographs of in vitro angiogenesis assays, showing tube-like structure formation by ECs, either alone or in
the presence of VEGF (10 ngml− 1) (positive control) or nEVs and oEVs. Quantitative analysis of the number and length of branches and
percentage of vessel area (% area) of in vitro formed vessel-like structures is reported as mean± s.e.m. The results are representative of four
different experiments performed in triplicate (n= 4) (for length, *Po0.05 pos ctrl and nEVs vs neg ctrl; **Po0.01 oEVs vs nEVs; for % area,
***Po0.001 pos ctrl and nEVs vs neg ctrl, oEVs vs nEVs; for no. of branches, ***Po0.001 pos ctrl vs neg ctrl, **Po0.01 nEVs vs neg ctrl,
***Po0.001 oEVs vs nEVs). Scale bars indicate 50 μm. (e) Migration assays performed on ECs treated either without (none) or with nEVs or
oEVs. The results are representative of four different experiments performed in triplicate (n= 4) (**Po0.01, nEVs vs none, *Po0.05 oEVs
vs nEVs).
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oEV functional derangements depend on cargo
Particular attention has been paid to the horizontal transfer of
functional RNAs by EVs,8,9,32 and so in order to investigate the
possibility that nEV functional activity depends on RNA cargo,
nEVs were pretreated with RNAse and evaluated for their ability to
induce migration and tube-like structures. As shown in Figures 3a
and b, while RNAse-pretreated nEVs were not able to induce EC
migration or angiogenesis in vitro, they are still able to induce
vascular cell adhesion molecule-1 expression resulting in mono-
nuclear cell adhesion (Figures 3c and d). miR-126's pro-angiogenic
properties prompted us to investigate whether miR-126 contributes
to EV-mediated biological function. nEVs that had been obtained
after nASCs were treated with miR-126 antagomir (Supplementary
Figures S2A and B) were used in the biological assay. Again, this
treatment prevents nEV biological activity (Figures 3a and b). To
further validate the biological relevance of miR-126 in nEV
function, ECs were transfected with pre-miR-126, and oEVs were
used in the biological assays. Unlike observations in ECs
transfected with the scramble control, a partial improvement in
migration and tube-like formation was detected in ECs that
overexpress miR-126 (Figures 3e and f). The reduced VEGF content
in oEVs led us to evaluate whether the addition of VEGF may be
more effective in mediating migration and tube-like structure
formation than miR-126 overexpression alone. Indeed, we found
that migration and tube-like structure formation was almost
completely recovered when ECs that overexpress miR-126
were also stimulated with VEGF (Figures 3e and f). These data
indicate that reduced miR-126 and VEGF content impact on oEV
biological action.
Reduced miR-126 expression in oEVs increases the content of
Spred1 and interferes with extracellular signal–regulated kinase
1/2 (Erk1/2) mitogen-activated protein kinase (MAPK) activation
The miR-126 pro-angiogenic effect was originally correlated with
its suppression of Spred1 expression and the inhibition of the
MAPK signaling pathway.35 Spred1 content and Erk1/2 MAPK
activation were thus evaluated in ECs that had been challenged
with nEVs and oEVs. nEVs were able to reduce Spred1 content
resulting in Erk1/2 MAPK activation (Figures 4a and b), which is
consistent with increased miR-126 expression. As expected,
Spred1 content increased and Erk1/2 activation decreased when
oEVs were used to stimulate ECs (Figures 4a and b). Similar results
were obtained when miR-126-depleted nEVs were used
(Figures 4a and b). To confirm the above results, ECs that
overexpress miR-126 were analyzed for Spred1 expression and
Erk1/2 MAPK activation in response to oEVs. As reported in
Figures 4c and d, miR-126 overexpression in ECs led to Spred1
downregulation and Erk1/2 MAPK activation.
nASC-derived EVs recapitulate oEV cargo after PA treatment
Elevated non-esterified fatty acid (NEFA) plasma levels are
commonly found in obese subjects.36 We therefore sought to
determine whether high NEFA concentrations can account for the
deranged oEV cargo. PA was used to treat nASC prior to EV
recovery as it accounts for approximately 30% of total plasma
NEFAs. No changes in EV number or size were detected under
these experimental conditions (data not shown). VEGF, MMP-2
and miR-126 content were thus analyzed. The results reported in
Figures 5a and b demonstrate that EV cargo was comparable to
that of oEVs. Moreover, EVs that were released after PA treatment
were again impaired in their ability to induce EC migration, tube-like
formation and activate the Erk1/2 MAPK pathway (Figures 5c and e),
when functional and biochemical experiments were performed.
To further confirm our hypothesis, nASC treated with PA were
analyzed for proliferation rate and senescence. Data reported in
Supplementary Figures S3A and B demonstrate that PA-treated
nASCs mirror oASC features. Finally, the effect of HG treatment on
EV functional capability was also evaluated, as diabetes is a part of
natural history of obesity. EVs were recovered from oASCs that
had undergone HG treatment and were evaluated for VEGF,
MMP-2 and miR-126 content. We found that, while a significant
reduction in miR-126 content was detected under these experi-
mental conditions (Figure 5a), VEGF and MMP-2 content were not
further reduced by HG treatment (Figure 5b). Moreover, HG
treatment further impaired oEV ability to promote EC migration
and tube-like structure formation (Figures 5c and e). No significant
reduction in the number of viable cells was detected.
EVs recovered from the subcutaneous tissue of obese patients are
also impaired in their pro-angiogenic potential
ASCs recovered from subcutaneous adipose tissue have been the
object of the most frequent studies because of their regenerative
capabilities.33 We therefore sought to investigate whether EVs that
are released from these tissue-derived ASCs may be more efficient
than oEVs. To this end, the effects of EVs released from
subcutaneous tissue-derived ASCs of the same obese subjects
(soEVs) and controls (snEVs) were evaluated. ASC stemness was
validated by analyzing the expression of Oct4 (Figure 6a). We
failed to detect differences in the number and size of sEVs in
obese subjects and controls (Figures 6b and c). soEV biological
activity was therefore evaluated and compared with that of snEVs.
As reported in Figures 6d and e, soEV treatment led to reduced EC
migration, a significant reduction in tube-like structure formation
and in the number and length of branches. No significant
reduction in the number of viable cells was detected. Moreover,
soEVs carried lower VEGF, MMP-2 and miR-126 content than snEVs
(Figures 6f and g). These data indicate that soEVs are also
significantly impaired in their pro-angiogenic potential.
DISCUSSION
We have shown in the present study that EVs that are released
from adipose tissue-derived ASCs of obese subjects are impaired
in their pro-angiogenic potential. In particular, we have noticed
that, unlike nEVs, oEVs bore reduced VEGF, MMP-2 and miR-126
content. This translates into reduced oEV capability to promote EC
migration and tube-like structure formation. We also found that
oEV impairment may depend on circulating levels of obesity-
associated PA. These results indicate that obesity negatively
impacts on ASC-derived EV functional capability and thus raises
concerns as to their clinical use.
Regenerative medicine, and in particular cell-based therapy, has
recently gained extensive attention, and various cell types,
including ASCs, have been proposed for this role.3–5 The positive
effects of ASC transplantation have recently been demonstrated
to result from their ability to release trophic mediators (paracrine/
autocrine hypothesis).9,10 There is increasing evidence to suggest
that ASC-secreted molecules, biologically present in the form of
vesicles, may act as paracrine/endocrine mediators that are
capable of modifying target cell functional capability.9,10 Vesicles,
which have distinct biogenesis or cell origin,37 include exosomes,
derived from the endosomal membrane compartment by
exocytosis, and microvesicles generated by the budding of cell
plasma membranes38 and are collectively denoted as EVs. EVs
have recently been the focus of intense attention for their role as
cell-to-cell communication mechanisms.13,14 In this regard, it has
been reported that ASC-derived EVs are able to induce pro-
angiogenic signals.17,33 The advantages of using EVs as an
alternative therapeutic option with which to treat obesity-
related vascular damage have led us to investigate the potential
clinical applications of obese-derived ASC EVs. We demonstrate
that the number and size of EVs released from visceral tissue-
derived ASCs are comparable in obese and non-obese subjects.
Obesity impacts on miR-126 EV content
G Togliatto et al
106
International Journal of Obesity (2016) 102 – 111 © 2016 Macmillan Publishers Limited
Figure 3. EV-mediated miR-126 transfer is required for EV functional activities. (a) Migration assays performed on ECs treated with EVs
recovered from nASCs that had either been treated with anti-miR-126 antagomir or nEVs+5U RNAse or not at all. The results are
representative of five different experiments performed in triplicate (n= 5) (***Po0.001 nEVs vs none; nEVs+anti-miR-126 and nEVs+5U
RNAse vs nEVs). (b) Representative photomicrographs of in vitro angiogenesis assays, showing tube-like structure formation by ECs treated
as above. Quantitative analysis of the number and length of branches and percentage of vessel area (% area) of in vitro formed vessel-like
structures is reported as mean± s.e.m. The results are representative of four different experiments performed in triplicate (n= 4) (for length,
*Po0.05 nEVs+RNAse vs nEVs; for % area, ***Po0.001 nEVs+RNAse and nEVs+anti-miR-126 vs nEVs; for no. of branches, **Po0.01 nEVs
+RNAse and nEVs+anti-miR-126 vs nEVs). Scale bars indicate 50 μm. (c) Cell extracts from ECs treated with nEVs or nEVs+5U RNAse were
analyzed for vascular cell adhesion molecule-1 (VCAM-1) content and normalized to β-actin content. IL-3-treated ECs were used as a
positive control (c+). The results are representative of five different experiments performed in triplicate (n= 5) (**Po0.01 nEVs and nEVs
+5U RNAse vs none). (d) The adhesion assay was performed by plating red-labeled peripheral blood mononuclear cells on an EC monolayer
that had been previously treated, or not, with nEVs or nEVs+5U RNAse. Adherent cells were counted and reported as mean± s.e.m.
per field (×20 magnification). The results are representative of five different experiments performed in triplicate (n= 5) (*Po0.05 nEVs and
nEVs+5U RNAse vs none). (e) Migration assays performed on ECs, pretreated with pre-miR-126 precursor or pre-miR-negative control (pre-
miR neg) and then stimulated with oEVs. EC migration was also evaluated on cells overexpressing miR-126 in the presence of oEVs and of
VEGF (10 ngml–1). The results are representative of four different experiments performed in triplicate (n= 4) (***Po0.001 ECs/pre-miR-126
+oEVs and ECs/pre-miR-126+oEVs+VEGF vs ECs/pre-miR neg+oEVs; ***Po0.001 ECs/pre-miR-126+oEVs+VEGF vs ECs/pre-miR-126+oEVs).
(f) Representative photomicrographs of in vitro angiogenesis assays performed on ECs treated as indicated in panel (c). Quantitative
analysis of the number and length of branches and percentage of area of in vitro formed vessel-like structures is reported as mean± s.e.m.
The results are representative of four different experiments performed in triplicate (n= 4) (for % area and no. of branches, **Po0.01
ECs/pre-miR-126+oEVs vs ECs/pre-miR neg+oEVs, ***Po0.001 ECs/pre-miR-126+oEVs+VEGF vs ECs/pre-miR neg+oEVs). Scale bars
indicate 50 μm.
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In addition, we have found that both oEVs and nEVs are able to
cross the plasma membrane and to release their cargo within
target cells, ECs. However, functional studies demonstrate that
oEVs are biologically inactive, as they were unable to induce EC
migration and tube-like structure formation. The EV mechanism of
action is known to rely on their ability to transfer functional
proteins and RNAs to target cells.14 A number of proteins and miRs
are carried by EVs, including those that participate in the
angiogenic process.39 VEGF, MMP-2 and miR-126 content was
found to be lower in oEVs than in nEVs, and this is consistent with
Figure 4. miR-126 oEV cargo drives Spred1 content and Erk1/2 activation in ECs. (a, b) Cell extracts from ECs treated with nEVs, oEVs or nEVs
+anti-miR-126 were analyzed for Spred1 (a) and pErk1/2 (b) content, normalized to β-actin and Erk1/2 content, respectively. (**Po0.01 for
Spred1 and ***Po0.001 for pErk1/2 oEVs and nEVs+anti-miR-126 vs nEVs, n= 4 performed in triplicate). (c, d) ECs either pretreated with pre-
miR-126 precursor or pre-miR-negative control (pre-miR neg) and then stimulated with oEVs were lysed and analyzed for Spred1 (c) and
pErk1/2 (d) content. Protein level was normalized to β-actin and Erk1/2 content, respectively. The results are representative of four different
experiments performed in triplicate (n= 4) (***Po0.001 ECs/pre-miR-126+oEVs vs ECs/pre-miR neg+oEVs).
Figure 5. EVs derived from PA-treated nASCs recapitulate oEV cargo. (a) miR‐126 expression was evaluated by quantitative real-time PCR either
on nEVs and nEVs recovered from nASC pretreated with PA (300 μmol l− 1), left panel, or on oEVs and oEVs recovered from oASC pretreated
with HG (25mmol l− 1). Data normalized to RNU6B are representative of four different experiments performed in triplicate (n= 4). (***Po0.001
PA nEVs vs nEVs; HG oEVs vs oEVs). (b) nEVs, PA nEVs, oEVs and HG oEVs, obtained as described above, were analyzed for VEGF and MMP-2
content and normalized to CD63 content. (**Po0.01 PA nEVs vs nEVs for VEGF and MMP-2, n= 4 performed in triplicate). (c) Cell extracts from
ECs treated with nEVs or PA nEVs were analyzed for Spred1 and pErk1/2 content. The protein level was normalized to β-actin and Erk1/2
content, respectively. (**Po0.01 PA nEVs vs nEVs for Spred1; ***Po0.001 nEVs vs nEVs for pErk1/2, n= 4 performed in triplicate).
(d) Representative photomicrographs of in vitro angiogenesis assays, showing tube-like structure formation by ECs treated with nEVs, PA nEVs,
oEVs or HG oEVs. Quantitative analysis of the number and length of branches and percentage of vessel area (% area) of in vitro formed vessel-
like structures is reported as mean± s.e.m. The results are representative of four different experiments (n= 4) performed in triplicate (for
length, ***Po0.001 PA nEVs vs nEVs; for % area, ***Po0.001 PA nEVs vs nEVs; for no. of branches, ***Po0.001 PA nEVs vs nEVs). Scale bars
indicate 50 μm. (e) Migration assays performed on ECs untreated or treated as indicated. The results are representative of four different
experiments (n= 4) performed in triplicate (**Po0.01 nEVs vs none; ***Po0.001 PA nEVs vs nEVs; ***Po0.001 oEVs and HG oEVs vs nEVs).
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the functional studies. Moreover, gain- and loss-of-function
experiments have shown that miR-126 is necessary if EVs are to
trigger angiogenic signals via Spred1 downregulation and Erk1/2
MAPK pathway activation. Finally, the finding that the addition of
VEGF to ECs that overexpress miR-126 was able to almost
completely restore migration and tube-like structure formation
further sustains the role that EV cargo has in mediating their
biological actions.
Obesity is associated with a chronic elevation of NEFAs, and PA
is one of the most abundant circulating NEFAs in obese patients.36
PA has been shown to act as an endogenous signaling molecule in
various cellular contexts.25 In particular, PA has recently been
linked to obesity-associated neurodegenerative diseases.40 We
herein provide evidence to suggest that elevated PA concentra-
tions can induce changes in ASC-derived EV cargo and that this
event translates into impaired EV-mediated pro-angiogenic signal
activation. Moreover, in a reflection of results in oEVs, EVs released
by ASCs from non-obese subjects that were challenged with PA
carried reduced VEGF, MMP-2 and miR-126 content. This suggests
that increased PA concentrations in obesity may be relevant in
changing ASC-derived EV cargo.
Alternatively, it is conceivable to hypothesize that oEV content
reflects the cellular phenotype changes occurring in obese
patients. In fact, the microenvironment has been shown to modify
both EV miR and protein profile.41,42 Consistent with this
possibility, our PA experiments suggest that altering nASC lipid
composition modifies EV cargo and functions. Comparative
lipidomic analysis of nASCs and oASCs EVs, not evaluated in this
study, might provide further explanations for the observed
different biological activities of EVs.
Obesity is a leading risk factor for the development of type 2
diabetes, and480% of adults who suffer from type 2 diabetes are
Figure 6. EVs recovered from the subcutaneous tissue of obese patients are impaired in their pro-angiogenic potential as well.
(a) Representative Oct4 content obtained from cell extracts of subcutaneous-derived ASCs (snASCs, n= 6; soASCs, n= 10). Protein levels were
normalized to tubulin content. pos: positive control, human ASCs purchased from Lonza; neg: negative control, adipocytes derived from the
NIH 3T3L1 cell line) (***Po0.001 neg vs pos control). (b) Representative images of NanoSight analyses performed on the 100 k fraction of
subcutaneous ASC-derived EVs. Curve 1, relationship between particle distribution (left y axis) and particle size (x axis); curve 2, correlation
between cumulative percentage distribution of particles (percentile in right y axis) and particle size (x axis). (c) Number of EV particles
(mean± s.e.m.) per cell at isolation. Data refer to EVs from subcutaneous adipose tissue samples recovered from obese subjects (soEVs, n= 10)
and non-obese subjects (snEVs, n= 6). (d) Representative photomicrographs of in vitro angiogenesis assays, showing tube-like structure
formation by ECs treated with snEVs or soEVs. Quantitative analysis of the number and length of branches and percentage of vessel area (%
area) of in vitro formed vessel-like structures is reported as mean± s.e.m. The results are representative of four different experiments (n= 4)
performed in triplicate (for length, ***Po0.001 soEVs vs snEVs; for % area, ***Po0.001 soEVs vs snEVs; for no. of branches, ***Po0.001 soEVs
vs snEVs). Scale bars indicate 50 μm. (e) Migration assays performed on ECs untreated or treated with snEVs or soEVs. The results are
representative of four different experiments (n= 4) performed in triplicate (***Po0.001 snEVs vs none; ***Po0.001 soEVs vs snEVs). (f) miR‐
126 expression was evaluated by quantitative real-time PCR on snEVs and soEVs. Data normalized to RNU6B are representative of all samples
(snEVs, n= 6; soEVs, n= 10) (***Po0.001 soEVs vs snEVs). (g) VEGF and MMP-2 content was evaluated in snEVs and soEVs. Protein levels were
normalized to CD63 content. (**Po0.01 soEVs, n= 10, vs snEVs, n= 6).
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overweight or obese.43 Thus, although our obese subjects were
not diabetics, we sought to determine whether a diabetic milieu
may further impair EV bioactivity by changing their cargo.
Mocharla et al.44 and Jansen et al.45 have shown reduced
miR-126 content in EVs released by CD34+ peripheral blood
mononuclear cells and ECs in a diabetic setting. As stated above,
we have noticed that obese-derived ASCs release EVs that are
already impaired in their miR-126 content and that the
hyperglycaemic milieu additionally harms miR-126 cargo and EV
bioactivity.
Easy access by minimally invasive methods means that
subcutaneous adipose tissue is of special interest as it is an
abundant source of ASC-derived EVs that can be exploited in
regenerative medicine.10,11 As a matter of fact, the pro-angiogenic
potential of EVs released by subcutaneous tissue-derived ASCs has
been reported.17,34 This is not the case for EVs released from the
subcutaneous adipose tissue-derived ASCs of obese patients.
Indeed, they share a similar cargo and impaired bioactivity
with oEVs.
Despite the exciting results of cell-based approaches in several
clinical settings,46 the technique's true clinical impact is still open
to debate. The intrinsic features of EVs may make them suitable
ASC derivates for use in regenerative medicine.10,11 EVs also show
advantages over cell therapy as they are biocompatible and
do not expose patients to the risk of cell maldifferentiation.11
A general strategy for ASC-derived EV clinical use has been
proposed by Katsuda et al.47 However, it is necessary for the
molecules that underlie ASC-EV-mediated therapeutics to be
identified if we are to realize full clinical application. Our data
support the notion that miRs, and in particular EV miR-126 content
and miR126's target, impact on EV pro-angiogenic properties,
which is in agreement with miR screening and gene ontology
target analysis results.11,48
There is a need to study EVs in different pathological contexts
as it will furnish important information as to their potential
therapeutic applications in regenerative medicine. EVs would
appear to possess all the potential attributed to cell-based
medicines. However, we herein provide evidence which suggests
that the potential damaging effects of environmental cues must
be always taken into account if ASC-derived EV clinical applica-
tions are to be pursued.
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